Awiqli (Insulin Icodec)FIRST Once-Weekly Basal Insulin
Revolutionary ultra-long acting insulin that reduces injections from 365 per year to just 52. Master dosing, switching protocols, administration, and key pharmacist counseling points for NAPLEX.
Drug Overview
What Makes Awiqli Revolutionary?
Awiqli is the FIRST and ONLY once-weekly basal insulin approved for Type 2 Diabetes. It reduces the burden of daily injections from 365 per year to just 52 per year, improving adherence and quality of life while maintaining effective glycemic control.
| Brand Name | Awiqli |
| Generic Name | insulin icodec-abae |
| Manufacturer | Novo Nordisk |
| FDA Approval Date | March 26, 2026 |
| Indication | Type 2 Diabetes Mellitus (adults) |
| Classification | Ultra-long acting basal insulin analog |
| Route | Subcutaneous injection |
| Frequency | Once weekly (same day each week) |
| Pen Device | FlexTouch pre-filled pen (10-700 units per injection, 10-unit increments) |
| Half-Life | Approximately 196 hours (~8 days) |
| Time to Steady State | 3-4 weeks |
Mechanism of Action
Awiqli is an ultra-long acting insulin analog that binds to insulin receptors to lower blood glucose through the same mechanisms as endogenous insulin. Its unique molecular modifications enable once-weekly dosing.
Glucose Uptake
Facilitates glucose uptake in skeletal muscle and adipose tissue by promoting translocation of GLUT4 glucose transporters to the cell membrane.
Hepatic Glucose Production
Suppresses hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis in the liver.
Protein & Lipid Metabolism
Promotes protein synthesis and lipogenesis while inhibiting lipolysis and proteolysis, leading to anabolic effects.
Ultra-Long Duration
Molecular modifications (fatty acid chain) enable strong albumin binding and slow release, resulting in 196-hour half-life for once-weekly dosing.
NAPLEX Pearl:
The ultra-long half-life of 196 hours means it takes 3-4 weeks to reach steady state. This is why a 50% loading dose is used in Week 1 when switching from daily basal insulin - to bridge the gap until therapeutic levels are achieved.
Dosing & Switching Protocols
For Insulin-Naive Patients
Starting Dose: 70 units once weekly
Administer the same day each week. Monitor fasting blood glucose and titrate based on glycemic response.
Switching from Daily Basal Insulin
Step 1: Calculate Weekly Dose
Multiply current daily basal insulin dose by 7
Example: 30 units/day × 7 = 210 units/week
Step 2: Add 50% Loading Dose (Week 1 Only)
For Week 1 only, add 50% to bridge to steady state
Example: 210 units × 1.5 = 315 units for Week 1
Step 3: Week 2 Onwards
Return to standard weekly dose (daily dose × 7)
Example: 210 units per week starting Week 2
Missed Dose Protocol
If missed dose is within 4 days of scheduled day:
- Administer the dose as soon as possible
- Resume regular weekly schedule on the originally scheduled day
If missed dose is more than 4 days late:
- Skip the missed dose entirely
- Wait and take the next scheduled dose on the regular day
Dose Titration
- • Adjust dose based on fasting blood glucose measurements
- • Make adjustments no more frequently than once weekly
- • Due to long half-life, full effect of dose changes takes 3-4 weeks
- • Typical adjustments: increase or decrease by 10-20 units per week
- • Monitor closely for hypoglycemia when increasing doses
Administration
FlexTouch Pen Device
- • Pre-filled, disposable pen injector
- • Dose range: 10-700 units per injection
- • Dose increments: 10 units
- • No need to attach a needle until ready to inject
- • Use a new needle for each injection
Injection Technique
- 1. Same day each week - Choose a consistent day (e.g., every Monday)
- 2. Any time of day - Can be administered with or without meals
- 3. Rotate injection sites - Abdomen, thigh, or upper arm
- 4. Never reuse needles - Use a new needle for each injection
- 5. Do not inject into areas with lumps, swelling, or damaged skin
Storage Requirements
- • Unopened pens: Refrigerate at 36-46°F (2-8°C) until expiration date
- • In-use pens: Can be stored at room temperature (below 86°F/30°C) OR refrigerated
- • In-use duration: Up to 12 weeks (3 months) after first use
- • Do not freeze - Discard if frozen
- • Protect from light - Keep in original carton when not in use
Critical Pharmacist Considerations
Hypoglycemia Risk Pattern
Higher risk on Days 2-4 after injection when insulin exposure peaks. Counsel patients to be extra vigilant during this window.
- • Day 1 (injection day): Lower exposure, lower risk
- • Days 2-4: Peak exposure, HIGHEST hypoglycemia risk
- • Days 5-7: Exposure declining, moderate risk
Steady State Considerations
- • Takes 3-4 weeks to reach steady state due to 196-hour half-life
- • This is why a 50% loading dose is used in Week 1 when switching
- • Full glycemic effects of dose changes won't be seen for 3-4 weeks
- • Caution against frequent dose adjustments - allow time for stabilization
Drug Interactions
- • Increased hypoglycemia risk: Oral antidiabetics, GLP-1 agonists, ACE inhibitors, MAOIs, beta-blockers (may mask symptoms)
- • Decreased insulin effect: Corticosteroids, thiazide diuretics, thyroid hormones, atypical antipsychotics
- • Monitor closely: When starting/stopping interacting medications
Advantages Over Daily Basal Insulin
- • Reduces injection burden from 365/year to 52/year (86% reduction)
- • May improve adherence and quality of life
- • Provides stable basal coverage throughout the week
- • Simplifies insulin regimen management
Patient Counseling Points
Key Counseling Messages
- 1. Once weekly, same day: Inject on the same day every week (e.g., every Monday). Set a phone reminder to avoid missing doses.
- 2. Time of day: Can inject any time on your scheduled day, with or without food. Choose a time that fits your routine.
- 3. Injection sites: Rotate between abdomen, thigh, and upper arm. Don't inject in the exact same spot each week.
- 4. Missed dose within 4 days: Take it as soon as you remember, then resume your regular schedule.
- 5. Missed dose over 4 days: Skip it and wait for your next scheduled dose. Don't double up.
Hypoglycemia Awareness
- • Watch for symptoms: Shakiness, sweating, fast heartbeat, dizziness, hunger, confusion
- • Higher risk Days 2-4: Be extra cautious with blood sugar monitoring 2-4 days after your injection
- • Always carry fast-acting carbs: Glucose tablets, juice, or candy
- • Check before driving: Especially on high-risk days
- • Teach family members: How to recognize and treat severe hypoglycemia
Storage & Handling
- • Keep unused pens in the refrigerator
- • Once opened, can store in fridge or at room temperature for up to 12 weeks
- • Never freeze - throw away if frozen
- • Keep away from direct heat and light
- • Check insulin before each use - should be clear and colorless
- • Always use a new needle - never share needles or pens
When to Contact Healthcare Provider
- • Frequent low blood sugars (below 70 mg/dL)
- • Blood sugars consistently above target range
- • Signs of diabetic ketoacidosis (excessive thirst, frequent urination, nausea)
- • Severe allergic reaction (rash, difficulty breathing, swelling)
- • Unexplained weight gain or swelling
- • Questions about dose adjustments
NAPLEX High-Yield Facts
Must Know for the Exam
- • FIRST once-weekly basal insulin approved for Type 2 DM
- • Generic name: insulin icodec-abae
- • Half-life: 196 hours (ultra-long acting)
- • Insulin-naive starting dose: 70 units/week
- • When switching: daily dose × 7, +50% Week 1
- • Steady state: 3-4 weeks
Common Exam Questions
- • Missed dose protocol: within 4 days take, over 4 days skip
- • Hypoglycemia risk highest: Days 2-4 after injection
- • FlexTouch pen: 10-700 units, 10-unit increments
- • Storage: 12 weeks at room temp or refrigerated
- • Why loading dose? Bridge to steady state
Clinical Pearl: Why the Loading Dose?
The 50% loading dose in Week 1 when switching from daily insulin is critical because insulin icodec takes 3-4 weeks to reach steady state. Without the loading dose, patients would have subtherapeutic insulin levels during the first month, leading to hyperglycemia. This is a HIGH-YIELD concept for NAPLEX.
Practice Question Preview
A patient currently taking insulin glargine 40 units daily is switching to insulin icodec. What should their Week 1 dose be?
A) 280 units
B) 300 units
C) 350 units
D) 420 units
Frequently Asked Questions
Can Awiqli be used in Type 1 Diabetes?
No, Awiqli is only FDA-approved for Type 2 Diabetes Mellitus in adults. It has not been studied in Type 1 diabetes or pediatric populations.
How does Awiqli compare to insulin glargine or degludec?
Awiqli has a much longer half-life (196 hours vs 25-42 hours) allowing once-weekly dosing instead of daily. Glycemic control is similar, but patient preference may favor weekly over daily injections.
Why is the hypoglycemia risk higher on Days 2-4?
Insulin icodec reaches peak plasma concentrations 2-4 days after injection due to its gradual absorption and albumin binding. This corresponds with the highest insulin exposure and greatest hypoglycemia risk.
Can patients split their weekly dose into smaller injections?
No, Awiqli is specifically designed for once-weekly administration. Splitting the dose would alter the pharmacokinetic profile and is not recommended.
What if a patient forgets which day is their injection day?
Advise patients to keep a calendar, set phone reminders, or use a pill organizer with days labeled. Consistency is crucial for maintaining stable glycemic control.
Can Awiqli be mixed with other insulins?
No, Awiqli should not be mixed with any other insulin or diluted. It must be administered as a separate injection.
Master Insulin Therapy for Your NAPLEX Exam
Practice with 2,000+ questions including comprehensive coverage of basal insulins, dosing calculations, and patient counseling.